Trade Summary

2 weeks ago, Ra Capital Management, L.P., serving as Dir, 10% owner at Climb Bio, Inc. (CLYM), purchased 314,561 shares at $2.40 per share, for a total transaction value of $754,737.00. Following this transaction, Ra Capital Management, L.P. now holds 11,293,828 shares of CLYM.

This purchase represents a 3.00% increase in Ra Capital Management, L.P.'s stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, December 11, 2025 and publicly disclosed via SEC Form 4 filing on Monday, December 15, 2025, 4 days after the trade was made.

Climb Bio, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.